Royce & Associates’s Cantel Medical Corporation CMD Stock Holding History

Royce & Associates’s Portfolio CMD Stock Details CMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-439	Closed	-$35K	–	1202
2019 Q2	$35K	Sell	439 -9,093	-95%	-$639K	﹤0.01%	1067
2019 Q1	$638K	Buy	+9,532	New	+$722K	0.01%	899
2018 Q2	–	Sell	-12,543	Closed	-$1.4M	–	1279
2018 Q1	$1.4M	Hold	12,543	–	–	0.01%	926
2017 Q4	$1.29M	Sell	12,543 -1,457	-10%	-$145K	0.01%	930
2017 Q3	$1.32M	Hold	14,000	–	–	0.01%	902
2017 Q2	$1.09M	Hold	14,000	–	–	0.01%	953
2017 Q1	$1.12M	Buy	+14,000	New	+$1.11M	0.01%	963
2015 Q1	–	Sell	-42,338	Closed	-$1.83M	–	1311
2014 Q4	$1.83M	Sell	42,338 -4,100	-9%	-$168K	0.01%	985
2014 Q3	$1.6M	Sell	46,438 -12,000	-21%	-$424K	0.01%	1050
2014 Q2	$2.14M	Sell	58,438 -14,000	-19%	-$475K	0.01%	1028
2014 Q1	$2.44M	Sell	72,438 -17,900	-20%	-$591K	0.01%	1020
2013 Q4	$3.06M	Sell	90,338 -12,100	-12%	-$419K	0.01%	990
2013 Q3	$3.26M	Sell	102,438 -4,601	-4%	-$122K	0.01%	953
2013 Q2	$2.42M	Buy	+107,039	New	+$2.32M	0.01%	1020

Other funds holding CMD

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Royce & Associates's CMD Position: Q3 2019 in Review

Royce & Associates sold out of Cantel Medical Corporation (CMD) in Q3 2019, closing a stake of 439 shares — an estimated $35K sold.

Royce & Associates first reported a position in CMD in Q2 2013 and held it in 14 quarters. The position peaked at $3.26M in Q3 2013. 244 funds tracked by Wall St. Rank hold CMD as of Q3 2019.

Royce & Associates reported no remaining Cantel Medical Corporation position as of Q3 2019 after selling out during the quarter.
Royce & Associates sold 439 Cantel Medical Corporation shares in Q3 2019, an estimated $35K.
Royce & Associates first reported a position in Cantel Medical Corporation in Q2 2013 and held it in 14 quarters.
Royce & Associates's Cantel Medical Corporation position peaked at $3.26M in Q3 2013.
244 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q3 2019.

Based on Royce & Associates's 13F filing for Q3 2019, filed 13 Nov 2019.